Immune Thrombocytopenia

  • Thomas G. DeLougheryEmail author


This chapter discusses immune thrombocytopenia. Diagnosis is discussed as well as acute therapy. Patients who fail initial therapy are offered three choices of therapy: splenectomy, thrombopoietin agonists, and rituximab. Evans syndrome and ITP in pregnancy are also discussed.


Immune thrombocytopenia Rituximab Eltrombopag Romiplostim Rituximab Pregnancy Evans syndrome 

Suggested Reading

  1. Bussel J, Arnold DM, Grossbard E, Mayer J, Treliński J, Homenda W, Hellmann A, Windyga J, Sivcheva L, Khalafallah AA, Zaja F, Cooper N, Markovtsov V, Zayed H, Duliege AM. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018;93(7):921–30.CrossRefGoogle Scholar
  2. Bylsma LC, Fryzek JP, Cetin K, Callaghan F, Bezold C, Mehta B, Wasser JS. Systematic literature review of treatments used for adult immune thrombocytopenia in the second-line setting. Am J Hematol. 2019;94(1):118–32.CrossRefGoogle Scholar
  3. Cooper N. State of the art – how I manage immune thrombocytopenia. Br J Haematol. 2017 Apr;177(1):39–54.CrossRefGoogle Scholar
  4. Kelton JG, Vrbensky JR, Arnold DM. How do we diagnose immune thrombocytopenia in 2018? Hematology Am Soc Hematol Educ Program. 2018;2018(1):561–7.CrossRefGoogle Scholar
  5. Neunert CE, Cooper N. Evidence-based management of immune thrombocytopenia: ASH guideline update. Hematology Am Soc Hematol Educ Program. 2018;2018(1):568–75.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of Hematology/Medical Oncology, Department of Medicine, Pathology, and PediatricsOregon Health & Sciences UniversityPortlandUSA

Personalised recommendations